News
Enhertu reduces breast cancer disease progression or death by 72%
New data presented at the 2021 European Society for Medical Oncology (ESMO) congress showed AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) can reduce disease progression or death in women with HER2-positive metastatic breast cancer.